Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

Cardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking the earliest signs of coronary artery clogs.

3 Feb 2010

Cardiac catheterization: A groundbreaking tool in the field of cardiology

Cardiac catheterizations have been a groundbreaking tool in the field of cardiology. This procedure offers a minimally invasive means for obtaining important information about the heart and its blood vessels, while also providing a less invasive treatment for certain heart conditions.

2 Feb 2010

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

People who are obese and have type 2 diabetes in their 20s will be at higher risk of having a heart attack or stroke in their 40s if they do not change their lifestyle.

30 Jan 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

FDA approves LPI's Perindopril Erbumine tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly.

29 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

27 Jan 2010

NCMHD awards Weill Cornell Medical College $8M for establishing CEDREC in New York City

Weill Cornell Medical College has established a new research center to improve medical care in ethnically diverse and medically underserved communities in New York City.

23 Jan 2010

Vivian and Seymour Milstein Family Heart Center to open to patients in February

Ushering in a new era in comprehensive cardiac care, the Vivian and Seymour Milstein Family Heart Center celebrated its opening today at NewYork-Presbyterian Hospital/Columbia University Medical Center.

21 Jan 2010

Omega-3 fatty acids may protect against cellular aging in coronary heart disease patients

Patients with coronary heart disease who had higher omega-3 fatty acid blood levels had an associated lower rate of shortening of telomere length, a chromosome marker of biological aging, raising the possibility that these fatty acids may protect against cellular aging, according to a study in the January 20 issue of JAMA.

20 Jan 2010

Besides LDL, Lp(a) can also increase risk for heart disease

LDL isn't the only "bad boy" when it comes to cholesterol. According to a new study, a lipoprotein in the bloodstream called Lp(a) — pronounced "LP little A" — can be labeled "bad cholesterol."

20 Jan 2010

Cardiac RSR test can quickly and accurately detect the presence of S-CAD

Testing a patient's cardiac respiratory stress response (RSR) can quickly and accurately detect the presence of significant coronary artery disease (S-CAD), according to new research published in the current issue of Cardiovascular Revascularization Medicine.

20 Jan 2010

New issue from Annals of Internal Medicine

Prescriptions of some opioids, such as oxycodone, have increased significantly over the past decade. As long-term opioid therapy for chronic noncancer pain becomes more common, the deaths associated with opioids increase.

19 Jan 2010

HDL launches new preventative model to help physicians manage chronic diseases

Health Diagnostic Laboratory Inc. (HDL), www.hdlabinc.com, announced today the launch of its new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions.

19 Jan 2010

U-M's tailored treatment more effective against heart attacks

A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better.

19 Jan 2010

FDA approves Celsius RMT ThermoCool catheter for use with Stereotaxis' magnetic navigation system

Stereotaxis announced that the Celsius® RMT ThermoCool® catheter has been approved by the U.S. Food and Drug Administration for use with Stereotaxis' magnetic navigation system for the treatment of Type 1 atrial flutter. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for mapping and ablation.

12 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010